India Globalization Capital

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for Research and Training in Artificial Intelligence (“CINFONIA”). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treat.

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.

IGC Pharma Reports Second Quarter Fiscal 2024 Results

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer's Association International Conference.

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research.

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Announces a $3 Million investment: strengthen IGC's working capital & support the advancement of our IGC-AD1 Phase-2 clinical trial.

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC received Notice of Allowance from Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures.

IGC Pharma Receives Notice of Allowance for Patent on Seizures

POTOMAC, Maryland--(BUSINESS WIRE)-- #IGC--Professor T. Govindaraju, IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award .

IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award

Presentation on Tuesday, June 6 at 3:00 PM PT Los Angeles, California--(Newsfile Corp. - May 18, 2023) - IGC Pharma, Inc. (NYSE American: IGC) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.

IGC Pharma to Present at LD Micro Invitational XIII

POTOMAC, MD / ACCESSWIRE / April 18, 2023 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023, at 4:30 PM (Local Time -PDT). Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principal Financial Officer, will be hosting the presentation and answering questions at the conclusion.

IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023

POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma's strategic focus and vision for the future.

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quarter 2023 financial results.

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia Grimaldi, PFO, will be featured in an investor webinar hosted by Radius Research on Friday, Feb. 10, at 12:30 p.m. ET. They will discuss the Company's Phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer's and will participate in a question and answer session.

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

DALLAS--( BUSINESS WIRE )--Over the past year the influencer marketing industry remained resilient and continued to grow in its role and impact for marketers, reaching an estimated value of $16.4 billion1. And, in 2023, the creator marketing industry shows no signs of slowing down. LTK, the creator-guided shopping platform and global creator marketing platform, today released its State of Creator Guided Shopping Trends Report to help brands as they look to harness the power of creators to grow their business.

LTK Releases 2023 State of Creator Guided Shopping Trends Report

POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection letter from Health Canada for approval of its trial, “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease.” The no objection letter provides the acknowledgement of IGC-AD1's drug candidacy and the authority to proceed with Phase 2 trials in Canada.

IGC Receives No Objection Letter from Health Canada

POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at https://www.sec.gov/.

IGC Announces Updated Life Sciences Presentation

POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was signed into law by President Biden on Friday Dec. 2, 2022. The law provides legislation establishing a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development.

IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act

POTOMAC, Md.--( BUSINESS WIRE )--India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease”.

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer's Disease

POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am ET and will be available for one-on-one meetings on Monday, December 5 and Tuesday, December 6.

News for India Globalization Capital Stock (IGC)